<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia, renal insufficiency, increase of mortality due to cardio vascular disease </DESCRIPTION>
<SEVERITY>Contraindication</SEVERITY>
<COMMENT>-for patients with diabetes or renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>The plasma concentrations of aliskiren increase by nearly 5 times and increase of the risk of its undesirable effects. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardio vascular disease</DESCRIPTION>
<SEVERITY>Contraindication </SEVERITY>
<COMMENT>-for patients with diabetes or renal insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>The plasma concentrations of aliskiren increase by nearly 6 times and increase of the risk of its undesirable effects. </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="GRAPEFRUIT (JUICE AND FRUIT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA71" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.

</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SACUBITRIL" rxcui="1656328">
</DRUG>
</DRUG2>
<DESCRIPTION>With patients who have diabetes or renal insufficiency, increase of the undesirable effects such as hypotension, hyperkalemia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>24-ALISKIREN.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09DX02" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C09BB10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring</COMMENT>
</INTERACTION>
</INTERACTIONS>
